Dydo Pharma News Today

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2023 Earnings Call Transcript February 29, 2024 Catalyst Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome to the Catalyst Pharmaceuticals Inc. Fourth Quarter and Full Year 2023 Financial Results Conference […]

Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022

29.02.2024 -     Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to Fourth Quarter 2022 Reported 2023 GAAP ...

CORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") CPRX, a commercial-stage biopharmaceutical company focused…

     Third Quarter 2023 Total Net Revenues of $102.7 Million, a 79.4% Increase YOY Third Quarter 2023 GAAP Net Loss per Share of $ Diluted, Impacted by an $81.5 Million One Time Non-Recurring...

Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results ...

Achieved Record Q2 2023 Total Net Revenues of $99.6 MillionAchieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOYAchieved 2023 Second Quarter GAAP EPS Diluted of...

Operator: Greetings and welcome to the Catalyst Pharmaceuticals first quarter 2023 financial results conference call. At this time, all participants are in a listen-only mode.

Reports Record Total Revenues of $85.4 Million for Q1 2023 Delivers Revenue Growth of 98%, a Record Increase YoY GAAP EPS Diluted of $0.26 Per Share; a...

Reports Record Total Revenues of $85.4 Million for Q1 2023 Delivers Revenue Growth of 98%, a Record Increase YoY GAAP EPS Diluted of $0.26 Per Share; a 117% Increase YoY Non-GAAP EPS Diluted... | May 10, 2023